Physician profile
Asif Azeem
NPI 1932288248
$7,025.45
in general payments reported to CMS, 2019-2025
35 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $800 · 2021: $929 · 2022: $1,057 · 2023: $1,106 · 2024: $1,025 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,178 · Education: $84.02 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,177.59 |
| Education | $84.02 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,521.54 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Janssen Biotech, INC. | $1,073.25 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $953.02 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Braintree Laboratories, INC. | $623.23 | 2019-2025 | Sutab, Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $369.38 | 2019-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $352.95 | 2019-2024 | Dificid |
| Celgene Corporation | $274.26 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $204.97 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $192.35 | 2019-2024 | Ocaliva |
| Pfizer INC. | $127.73 | 2022-2025 | |
| Lilly USA, LLC | $122.83 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $109.39 | 2020-2024 | |
| Genzyme Corporation | $99.93 | 2022-2025 | |
| Madrigal Pharmaceuticals | $97.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Shionogi INC | $96.34 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $93.34 | 2023-2024 | Dupixent |
| Daiichi Sankyo INC. | $90.57 | 2019-2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $73.47 | 2021-2022 | |
| Celltrion USA INC. | $64.66 | 2025 | Vegzelma |
| Sandoz INC. | $62.79 | 2024 | Hyrimoz |
| Ucb, INC. | $48.93 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $45.07 | 2024 | Bylvay, Iqirvo |
| Fresenius Kabi USA, LLC | $42.98 | 2023 | Idacio |
| Alexion Pharmaceuticals, INC. | $42.43 | 2019 | |
| Ardelyx, INC. | $37.61 | 2023 | Ibsrela |
| Aimmune Therapeutics, INC. | $37.26 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $30.41 | 2021-2023 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $26.71 | 2022 | |
| Novo Nordisk INC | $22.06 | 2025 | Wegovy |
| Mylan Institutional INC. | $19.61 | 2023 | Hulio |
| Phathom Pharmaceuticals, INC. | $17.78 | 2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $15.12 | 2021 | |
| Olympus America INC. | $13.68 | 2021 | |
| Shire North American Group INC | $11.45 | 2019 | |
| Allergan, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asif Azeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.